Compliance with the RSV immunoprophylaxis dosing schedule in the Polish registry for palivizumab (2008-2014)

1Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003;48:209-231.Black CP Systematic review of the biology and medical management of respiratory syncytial virus infection Respir Care 200348209 231Search in Google Scholar

2Greenough A. Role of ventilation in RSV disease: CPAP, ventilation, HFO, ECMO. Pediatr Resp Rev. 2009;10:26-28.Greenough A Role of ventilation in RSV disease: CPAP, ventilation, HFO, ECMO Pediatr Resp Rev 20091026 2810.1016/S1526-0542(09)70012-0Search in Google Scholar

3Wiśniewska-Ligier A, Woźniakowska-Gęsicka T, Andrzejewski A, Wróblewska W. RSV infections remain dangerous. Article in Polish. Klin Pediatr 2008;16:42-46.Wiśniewska-Ligier A Woźniakowska-Gęsicka T Andrzejewski A Wróblewska W. RSV infections remain dangerous Article in Polish. Klin Pediatr 20081642 46Search in Google Scholar

4Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55.Nair H Nokes DJ Gessner BD Dherani M Madhi SA Singleton RJ O’Brien KL Roca A Wright PF Bruce N Chandran A Theodoratou E Sutanto A Sedyaningsih ER Ngama M Munywoki PK Kartasasmita C Simões EA Rudan I Weber MW Campbell H Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 20103751545 5510.1016/S0140-6736(10)60206-1Search in Google Scholar

5Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, Borok G, Butylkova Y, Wegzyn C. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatr Pulmonol. 2017;52:556-569.Stein RT Bont LJ Zar H Polack FP Park C Claxton A Borok G Butylkova Y Wegzyn C Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis Pediatr Pulmonol 201752556 56910.1002/ppul.23570Search in Google Scholar

6Rutkowska M, Helwich E, Borecka R, Gadzinowski J, Polak K, Czyżewska M, Kościesza A, Kornacka MK, Klimek M. Incidence of respiratory infections in children with bronchopulmonary dysplasia receiving prophylaxis with palivizumab. Article in Polish. Ped Pol. 2011;86:317-325.Rutkowska M Helwich E Borecka R Gadzinowski J Polak K Czyżewska M Kościesza A Kornacka MK Klimek M Incidence of respiratory infections in children with bronchopulmonary dysplasia receiving prophylaxis with palivizumab Article in Polish. Ped Pol 201186317 32510.1016/S0031-3939(11)70495-4Search in Google Scholar

7Borecka R, Lauterbach R, Helwich E. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland. Dev Period Med. 2016;20:181-190.Borecka R Lauterbach R Helwich E Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland Dev Period Med 201620181 190Search in Google Scholar

8Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL; CARESS investigators. Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J. 2015;34:e290-297.Chan P Li A Paes B Abraha H Mitchell I Lanctôt KL; CARESS investigators. Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab Pediatr Infect Dis J 201534e290 29710.1097/INF.0000000000000922Search in Google Scholar

9Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab outcomes Study Group. Pediatr Infect Dis J. 2000;19:1068-1071.Sorrentino M Powers T Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab outcomes Study Group Pediatr Infect Dis J 2000191068 107110.1097/00006454-200011000-00007Search in Google Scholar

10Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab outcomes Registry. J Perinatol. 2008;28:511-517.Frogel M Nerwen C Cohen A VanVeldhuisen P Harrington M Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab outcomes Registry J Perinatol 200828511 51710.1038/jp.2008.28Search in Google Scholar

11Simon A, Nowak H, Sterz R. Use of palivizumab in Germany: data from 2002-2007. Klin Padiatr. 2011;223:292-298.Simon A Nowak H Sterz R Use of palivizumab in Germany: data from 2002-2007 Klin Padiatr 2011223292 29810.1055/s-0030-1270515Search in Google Scholar

12Pignotti MS, Indolfi G, Donzelli G. Factors impacting compliance with palivizumab prophylaxis. Pediatr Infect Dis J. 2004;23:186-187.Pignotti MS Indolfi G Donzelli G Factors impacting compliance with palivizumab prophylaxis Pediatr Infect Dis J 200423186 18710.1097/01.inf.0000110271.48794.a7Search in Google Scholar

13Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143:S118-S126.Simoes EA Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease J Pediatr 2003143S118 S12610.1067/S0022-3476(03)00511-0Search in Google Scholar

14Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002;21:512-518.Oh PI Lanctôt KL Yoon A Lee DS Paes BA Simmons BS Parison D Manzi P; Composs Investigators. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes Pediatr Infect Dis J 200221512 51810.1097/00006454-200206000-0000712182374Search in Google Scholar

15Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung-function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med. 1988;319:1112-1117.Martinez FD Morgan WJ Wright AL Holberg CJ Taussig LM Diminished lung-function as a predisposing factor for wheezing respiratory illness in infants N Engl J Med 19883191112 111710.1056/NEJM1988102731917023173442Search in Google Scholar

16Giardino AP, Tran XG, Whitmire DA. Respiratory syncytial virus prevention outreach project. Tex Med 2009;105:e1.Giardino AP Tran XG Whitmire DA Respiratory syncytial virus prevention outreach project Tex Med 2009105e1Search in Google Scholar

17Bernard L, Lecomte B, Pereira B, Proux A, Boyer A, Sautou V. Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants. Article in French. Arch Pediatr. 2015;22:146-153.Bernard L Lecomte B Pereira B Proux A Boyer A Sautou V Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants Article in French. Arch Pediatr 201522146 15310.1016/j.arcped.2014.11.01525534557Search in Google Scholar

18Lundeen K, Pfeiffenberger T, Jacobson Vann J, O’Brien T, Sampson C, Wegner S. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program. J Manag Care Pharm. 2013;19:115-124.Lundeen K Pfeiffenberger T Jacobson Vann J O’Brien T Sampson C Wegner S. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program J Manag Care Pharm 201319115 12410.18553/jmcp.2013.19.2.11523461427Search in Google Scholar